License, Commercialization And Supply Agreements (Details) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended
	Dec. 07, 2018	Oct. 01, 2016	Jun. 30, 2018 USD ($) $ / shares shares	Nov. 30, 2013	Jul. 31, 2013 country	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Sep. 30, 2017 USD ($)
License, Commercialization, and Development Agreements with Third Parties
Net revenue						$ 16,146	$ 11,900
SPEDRA | Menarini Group | Minimum
License, Commercialization, and Development Agreements with Third Parties
Number of European countries covered under the license agreement | country					40
PANCREAZE | Warrants Issued
License, Commercialization, and Development Agreements with Third Parties
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			61.60%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.91%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Janssen | PANCREAZE
License, Commercialization, and Development Agreements with Third Parties
Payments to Acquire Businesses, Gross			$ 135,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other			400
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accruals For Estimated Destruction Of Future Unsalable Inventory			6,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			$ 2,100
Willow Biopharma Member | PANCREAZE
License, Commercialization, and Development Agreements with Third Parties
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			357,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 3.70
Finite-Lived License Agreements, Gross			$ 141,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other			1,500
Willow Biopharma Member | PANCREAZE | Warrants Issued
License, Commercialization, and Development Agreements with Third Parties
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 800
License and commercialization agreement | PANCREAZE
License, Commercialization, and Development Agreements with Third Parties
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			10 years
Supply agreement | Sanofi Chimie
License, Commercialization, and Development Agreements with Third Parties
Long-term Purchase Commitment, Period	5 years
Additional period of auto-renewal	1 year
Supply agreement | Avanafil Tablets | Sanofi Winthrop | Minimum
License, Commercialization, and Development Agreements with Third Parties
Long-term Purchase Commitment, Period				5 years
Supply agreement | STENDRA/SPEDRA | Metuchen
License, Commercialization, and Development Agreements with Third Parties
Long-term Purchase Commitment, Period		5 years
Additional period of auto-renewal		2 years
Supply agreement | STENDRA/SPEDRA | Metuchen | Minimum
License, Commercialization, and Development Agreements with Third Parties
Termination notice of license and supply agreement		2 years
Supply agreement | License and Milestone Revenue | Alvogen
License, Commercialization, and Development Agreements with Third Parties
Net revenue								$ 2,500